SCHEMBL13459543

SCHEMBL13459543

Nc1ccc(-c2cccc3c([N+](=O)[O-])nccc23)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 1/20 0.39
▸ CA12 O43570 2/20 0.39
▸ CA1 P00915 2/20 0.39
▸ CA2 P00918 2/20 0.39
▸ CA9 Q16790 2/20 0.39
▸ PLG P00747 1/20 0.38
▸ ALDH1A1 P00352 2/20 0.37
▸ NPY1R P25929 2/20 0.36
▸ CLK1 P49759 1/20 0.36
▸ GSK3B P49841 1/20 0.36
▸ CDK5 Q00535 1/20 0.36
▸ CDK5R1 Q15078 1/20 0.36
▸ MEN1 O00255 3/20 0.36
▸ KMT2A Q03164 3/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ IDO1 P14902 2/20 0.36
▸ POLB P06746 1/20 0.36
▸ PRKCZ Q05513 1/20 0.36
▸ CYP1A2 P05177 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27947325 0.81 MEN1 (0.43) CA12CA1CA2CA9ALDH1A1
SCHEMBL13459941 0.80 ALDH1A1 (0.40) DYRK1ACA12CA1CA2CA9
SCHEMBL4511200 0.76 TGFBR1 (0.50) CA12CA1CA2CA9PLG
SCHEMBL11819002 0.74 TDP1 (0.64) ALDH1A1MEN1KMT2AKDM4ETDP1
SCHEMBL13459551 0.73 PLAU (0.44) ALDH1A1NPY1RMEN1KMT2AKDM4E
SCHEMBL13459534 0.70 PLG (0.39) DYRK1ACA12CA1CA2CA9
SCHEMBL27737402 0.68 CA12 (0.63) CA12CA1CA2CA9ALDH1A1
SCHEMBL10712973 0.67 ALDH1A1 (0.71) ALDH1A1MEN1KMT2ATDP1POLB
SCHEMBL985839 0.67 ALDH1A1 (0.50) ALDH1A1MEN1KMT2AKDM4ETDP1
SCHEMBL28001315 0.67 ALDH1A1 (0.69) CA12CA1CA2CA9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010032986-A2 NOVEL 5-(4-AMINOPHENYL)-ISOQUINOLINE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PRODUCTION METHOD FOR SAME, AND COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PROPHYLAXIS AND TREATMENT OF MEDICAL CONDITION INDUCED BY RAF KINASE HYPERACTIVITY 주식회사 이큐스팜 (KR) 2010-03-25 — — WO disclosed
Send feedback